Oral BBR-012 in the Treatment of Diabetic Foot Ulcers, Proof of Concept Study

• Status: Unknown status
• Trial end date: 2012-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this Clinical Proof of Principle study is to evaluate the effect of BBR-012 on the healing of complicated diabetic foot ulcers.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bridge BioResearch Ltd.

Criteria

Main Inclusion Criteria:

• Aged ≥18

• Diabetes mellitus

• Ischaemic or neuro-ischaemic Diabetic Foot Ulcer below the malleolus, but not wholly on the sole of the foot (minimum size: 1 cm x 1 cm)

• Body Mass Index(BMI) ≤40 kg/m2

• Women of childbearing potential must use acceptable methods of birth control

• Written informed consent to participate in the study

• Patients must be able to speak English fluently and to understand English

Main Exclusion Criteria:

• Any uncontrolled illnesses (e.g. active malignancy, vasculitis) that, in the opinion of the investigator, would interfere with interpreting the results of the study

• Infected Diabetic Foot Ulcer based on the IDSA guidelines, i.e. presence of purulent secretions or at least two of the manifestations of inflammation (erythema, warmth, swelling or induration and pain or tenderness), and for whom, in the investigator's judgment, intravenous or oral antibiotic therapy is required

• Active osteomyelitis

• Wholly plantar Diabetic Foot Ulcer

• Suspected gangrenous tissue of the affected limb that cannot be removed with a single debridement

• Diabetic Foot Ulcer associated with prosthetic material or a device

• Received any potentially effective systemic antibiotic therapy for more than 24 hours during the 72-hour period before the screening visit

• Is receiving, or has received within the 14 days prior to the screening visit, any concomitant topical wound therapy (e.g., topical antimicrobial therapy, topical debriding agent, topical growth factor, topical skin replacement, or hyperbaric oxygen)

• Has received systemic corticosteroids, immunosuppressive agents, radiation therapy or chemotherapy within the 30 days prior to the screening visit.

• Hepatic impairment, renal impairment (defined as estimated glomerular filtration rate <10 mL/minute/1.73m2), hypersensitivity to isoniazid.

• High risk for tuberculosis, e.g. HIV positive, are immunosuppressed, or have active malignancy

• Symptoms of active or latent tuberculosis (based on specific history, physical examination, Interferon Gamma Release Assay (IGRA) test and chest X-Ray)

• Known or suspected drug or alcohol abuse or positive drugs of abuse test.

• Participating in any clinical study the 12 weeks before the screening visit

• Donation of more than 450 mL of blood in the 3 months before the screening visit, or 1200 mL blood in the 12 months before the screening visit.

• History of severe hypersensitivity or ongoing hypersensitivity that might affect the patient's suitability for the study (e.g. hypersensitivity to wound dressings), as judged by the investigator.

• History of allergy to, or insensitivity to, local anaesthetics

• Use of any prescribed or non-prescribed (over-the-counter) medication, including herbal medication (e.g., St. Johns Wort) that could possibly interfere with the objectives of this study (e.g., could affect the closure of chronic dermal ulceration), during 2 weeks (or 5 half-lives of the compound whichever is the longer) before the anticipated first dose of study medication. Occasional paracetamol for pain relief (maximum 2 g per 24 hours) and adrenergic nasal spray for relief of nasal congestion are allowed

• Having received BBR-012 or isoniazid within the 6 months prior to the screening visit

• Bleeding disorder or history of increased bleeding